FAQs - Dianthus Therapeutics

On which exchange is Dianthus Therapeutics listed, what is the ticker symbol and when did it go public?

Dianthus Therapeutics’ stock is traded on the Nasdaq Capital Market under the symbol “DNTH”. The Company went public via a merger with Magenta Therapeutics, Inc. (MGTA) on September 11, 2023.

Where is the Dianthus Therapeutics corporate headquarters?

Dianthus Therapeutics is headquartered at 7 Times Square, New York, New York, 10036.

When is Dianthus Therapeutics’ fiscal year-end?

Dianthus Therapeutics’ fiscal year-end is December 31st.

Who is Dianthus Therapeutics’ transfer agent?

Dianthus Therapeutics’ transfer agent is Computershare.

150 Royall Street
Canton, MA 02021
800-446-2617

Who is Dianthus Therapeutics’ legal counsel?

Dianthus Therapeutics’ legal counsel is Gibson, Dunn & Crutcher LLP

Who is Dianthus Therapeutics’ independent auditor?

Dianthus Therapeutics’ auditor is Deloitte in Morristown, NJ.

Where can I find the latest corporate news releases and financial reports?

Dianthus Therapeutics’ press release archives can be viewed here.

Where can I find copies of Dianthus Therapeutics’ financial documents, including annual reports (Form-10K) and quarterly reports (Form 10-Q)?

Dianthus Therapeutics’ SEC filings can be found on https://www.sec.gov and can be viewed here.

What were the material U.S. federal income tax consequences of the reverse stock split, the receipt of the contingent value rights, and the merger?

The anticipated material U.S. federal income tax consequences of (i) the merger between Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) and Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.), (ii) the 1-for-16 reverse stock split effected by Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) on September 11, 2023, and (iii) the receipt of the contingent value rights (“CVRs”) distributed by Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) distributed on September 14, 2023, were summarized and discussed in the definitive proxy statement/prospectus filed with the Securities and Exchange Commission in connection with the merger (the “Proxy Statement / Prospectus”), which can be viewed here.

A U.S. Internal Revenue Service Form 8937 (Report of Organizational Actions Affecting Basis of Securities) for each of the merger and name change, the reverse stock split, the distribution of the CVRs, and the exchange of shares of Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.) for shares of Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) at the effective time of the merger can be found at the following links:

Form 8937 for Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.); and

Form 8937 for Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.).

For a complete description of the anticipated material U.S. federal income tax consequences of the receipt of CVRs by stockholders, see the section entitled “Agreements Related to the Merger—Contingent Value Rights Agreement—Material U.S. Federal Income Tax Consequences of the CVRs to Holders of Magenta Common Stock” beginning on page 208 of our Proxy Statement / Prospectus, which can be viewed here.

PLEASE CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL INCOME AND OTHER U.S. FEDERAL, STATE, LOCAL OR NON-U.S. TAX CONSEQUENCES OF THEREVERSE STOCK SPLIT, THE RECEIPT OF THE CVRs, OR THE MERGER, AS APPLICABLE TO YOUR OWN PERSONAL CIRCUMSTANCES.

When and where is the Annual Stockholders’ Meeting?

Our stockholders’ meeting will be held annually. Instructions on how to attend will be delivered to all stockholders.

Whom should I contact regarding investor inquiries?

Please email ir@dianthustx.com for assistance.

Where can I find out more about Dianthus Therapeutics?

To find out more about us, visit our webpage at dianthustx.com or sign up here to receive email alerts.